Mastery in Diabetes Management: Doxycycline Treatment for Insulin Resistance
Erjola Balliu, MD
Erjola Balliu, MD, of Stony Brook Hospital in New York, spoke with MedPage Today at ENDO 2017, the annual meeting of The Endocrine Society, where she reported finding that use of the antibiotic doxycycline was associated with improved fasting glucose when compared to placebo in a proof-of-concept study. Her full poster may be downloaded by clicking here.
Following is a transcript of her remarks:
Obesity is a state of inflammation and the inflammatory process may be contributing to the development of insulin resistance and the associated metabolic abnormalities such as dyslipidemia, diabetes, hypertension, and cardiovascular disease. We all know that obese individuals compared to normal weight individuals are four times more likely to develop diabetes, about two to four times more likely to develop heart disease, and about two times more likely to die from hypertension-related heart disease. So, it is very important to be able to reduce the prevalence of these health problems associated with obesity.
In the past, there have been a lot of trials looking at medications to reduce inflammation, but they've had a lot of serious side effects. They've looked at pioglitazone, but that is associated with bone loss and bladder cancer. They've used TNF-alpha antagonists and they are at increased risk for developing tuberculosis and myocardial infarction. They've used salicylates, but they cause very severe tinnitus and gastrointestinal symptoms. Metformin has shown to improve insulin sensitivity, but in those trials hypertension got worse.
So, we're very in need of a Continue reading